Clinical Trial

The Comparison of EBUS-TBNA, TBMC Via a Tunnel, and TBFB Via a Tunnel in Diagnosing Mediastinal Lymphadenopathy.

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 27, 2024 (before its estimated February 18, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this prospective, multi-centre, randomised controlled clinical study is to compare the diagnostic yield and safety of the three biopsy techniques (EBUS-TBNA, EBUS-TBMC via a tunnel, and EBUS-TBFB via a tunnel) in mediastinal/hilar lymph node biopsies. Participants will divided into EBUS-TBNA group, EBUS-TBMC via a tunnel group, and EBUS-TBFB via a tunnel group at a 1:1:1 ratio by using central, computerized random sequence, and then undertake EBUS-TBNA, EBUS-TBMC via a tunnel, or EBUS-TBFB according to the group. Researchers will compare the diagnostic yield and incidence of adverse events of the three biopsy techniques.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-02-08; most recent amendment 2024-08-24.
Status change: Not Yet Recruiting → Recruiting 2024-08-08
Trial Details
NCT Number NCT06262620
Lead Sponsor China-Japan Friendship Hospital
Conditions Lymphadenopathy Hilar, Lymphadenopathy Mediastinal
Enrollment 552 participants
Start Date 2024-03-01
Primary Completion 2026-02-18 (estimated)
Study Completion 2026-02-18 (estimated)
Updated on ClinicalTrials.gov 2024-08-27